Growth Factors and Cytokines

Growth factors are extracellular polypeptides that bind to cell surface receptors and trigger intracellular signaling cascades, resulting in cell proliferation and/or differentiation. Growth factors can be versatile, stimulating growth in a variety of different cell types (for example IGF-1), whilst others are cell-specific (for example erythropoietin acts solely on erythrocytes).

Growth Factors and Cytokines Products Targets

Products for Growth Factors and Cytokines - Page 7

Cat.No. Product Name Information/Activity
BCC5120 AV-412 free base AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.
BCC7356 BIBU 1361 dihydrochloride Selective inhibitor of EGFR-kinase
BCC1449 Canertinib dihydrochloride Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM.
BCC7667 CGP 52411 CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease.
BCC1306 3,3'-Diindolylmethane 3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.
BCN5499 Genistein Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
BCC7300 GW 583340 dihydrochloride 1173023-85-2
BCC7441 HDS 029 881001-19-0
BCC6046 HKI 357 HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
BCN2173 Gefitinib Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity.